Gene therapy trial for ABCA4-related retinal disease
Part of Eyes & vision clinical trials.
This trial tests a new gene therapy called ZVS106e for people with inherited retinal degeneration caused by changes in both copies of the ABCA4 gene. The therapy aims to slow or stop vision loss, and the study will check if it is safe and if it works.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 8 years old.
- A genetic test must confirm that your retinal disease is caused by changes in both copies of the ABCA4 gene (not other genes).
- Your vision in the treated eye must be between about 20/100 and 20/800 on a standard eye chart.
- If you are sexually active, you and your partner must agree to use effective birth control during the trial and for at least one year after the treatment.
- You must not have had certain eye surgeries (like retinal reattachment or vitrectomy) in the eye being treated.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study follows people with Stargardt disease (a genetic eye condition that causes vision loss) over time. It aims to learn more about how the disease progresses and does not test any treatment.
This trial tests a new gene therapy called ZVS203e for people with retinitis pigmentosa caused by a specific RHO gene mutation. It aims to see if the treatment is safe and can help improve vision.
This trial offers compassionate use of the gene therapy ZVS101e for people with Bietti crystalline dystrophy (BCD) who were in the control group of an earlier study. It aims to give extended treatment access to those who didn't receive the experimental therapy before.
This trial tests a new gene therapy called VG801 for people with Stargardt disease, a genetic condition that causes vision loss. The treatment aims to improve or slow vision loss by delivering a working copy of the ABCA4 gene to the retina.
This trial tests a new gene therapy, AAVB-039, for people with Stargardt disease caused by a specific gene mutation. The treatment is given during eye surgery and aims to slow or stop vision loss.
This trial tests a new gene therapy called SB-007 for people with Stargardt disease (STGD1). It is given as an injection under the retina to see if it is safe and can help slow vision loss.
Hear when a new Stargardt trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.